Johnson Investment Counsel Inc. Lowers Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Johnson Investment Counsel Inc. cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 32.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,683 shares of the financial services provider’s stock after selling 1,753 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in iShares Biotechnology ETF were worth $487,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Sigma Planning Corp increased its position in shares of iShares Biotechnology ETF by 11.7% during the third quarter. Sigma Planning Corp now owns 7,083 shares of the financial services provider’s stock worth $1,031,000 after purchasing an additional 743 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in iShares Biotechnology ETF during the 3rd quarter worth $36,000. Aptus Capital Advisors LLC grew its holdings in shares of iShares Biotechnology ETF by 36.5% during the third quarter. Aptus Capital Advisors LLC now owns 426 shares of the financial services provider’s stock worth $62,000 after buying an additional 114 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of iShares Biotechnology ETF by 0.7% in the third quarter. Oppenheimer & Co. Inc. now owns 35,663 shares of the financial services provider’s stock valued at $5,193,000 after buying an additional 237 shares during the last quarter. Finally, Main Street Financial Solutions LLC raised its holdings in iShares Biotechnology ETF by 1.9% in the 3rd quarter. Main Street Financial Solutions LLC now owns 8,152 shares of the financial services provider’s stock valued at $1,187,000 after acquiring an additional 150 shares during the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

IBB stock opened at $133.14 on Friday. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The firm has a market capitalization of $6.29 billion, a PE ratio of 24.52 and a beta of 0.84. The business has a 50 day simple moving average of $136.24 and a 200-day simple moving average of $140.01.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a dividend, which was paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.